Incyte Corporations in-depth stock price analysis indicates that the stock price has rallied 17.44% in the past 12 Weeks , but analyzing the 6 month charts for the stock , the price continues to stay positive and keep the rally at 50.17% . Looking at the past 52 week period, the stock price is up at 78.03% . Relative price strength is a important factor used by wealth management firms while investing in stocks because the indicator compares the stock performance with the overall market. The relative price strength of Incyte Corporation has a positive value of 38.36 compared to overall market. Incyte Corporation (NASDAQ:INCY) has climbed 1.13% in the past week and advanced 3.35% in the last 4 weeks. In the past week, the company has outperformed the S&P 500 by 0.31% and the outperformance has advanced to 1.5% for the last 4 weeks period.
Incyte Corporation (NASDAQ:INCY) stock ended Friday session in the red zone in a volatile trading. The stock closed down 1.26 points or 1.02% at $121.7 with 1,084,706 shares getting traded. Post opening the session at $123.01, the shares hit an intraday low of $121.26 and an intraday high of $123.1 and the price was in this range throughout the day. The company has a market cap of $22,926 million and the number of outstanding shares has been calculated to be 188,385,150 shares. The 52-week high of Incyte Corporation (NASDAQ:INCY) is $124.87 and the 52-week low is $55.
Incyte Corporation Last issued its quarterly earnings results on Nov 1, 2016. The company reported $0.19 EPS for the quarter, beating the analyst consensus estimate by $ 0.17. Analyst had a consensus of $0.02. The company had revenue of $269.50 million for the quarter, compared to analysts expectations of $261.42 million. The companys revenue was up 43.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.22 EPS.
Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Incyte Corporation was Initiated by Credit Suisse to Outperform on Jan 23, 2017.
Company has reported several Insider transactions to the SEC, on Jan 11, 2017, Reid M Huber (EVP, Chief Scientific Officer) sold 11,739 shares at 113.55 per share price.On Nov 17, 2016, Paula J Swain (EVP, Human Resources) sold 10,000 shares at 103.26 per share price.On Oct 11, 2016, Barry P Flannelly (EVP & General Manager US) sold 24,204 shares at 97.00 per share price.
Incyte Corp is a drug discovery company that is using its expertise in genomics, medicinal chemistry and molecular, cellular and in vivo biology to discover and develop novel therapeutics. The company has three fully-staffed drug discovery programs underway focused primarily on the identification of new small molecule drugs for cancer and inflammation. Incyte also has strategic alliances with Lexicon Genetics and Medarex focused on the discovery and development of protein therapeutics or antibodies to treat inflammatory diseases and cancer.